Samik Pharmaceutical is experiencing a surge in stock prices following news that the government is considering health insurance coverage for hair loss treatments. The company’s long-acting hair loss treatment platform technology has attracted investor interest.
As of 2:16 PM on June 15, Samik Pharmaceutical shares were trading at 7,700 won, up 29.85% from the previous trading day, according to the Korea Exchange.
The rise in stock prices appears to be influenced by reports that the government is exploring health insurance options for hair loss treatments aimed at young people. The Ministry of Health and Welfare plans to gather public opinions in the second half of this year to assess the potential expansion of health insurance coverage for hair loss treatments.
Health and Welfare Minister Jeong Eun-kyeong stated during a recent policy meeting that various opinions on the necessity of health insurance coverage for hair loss treatments would be collected before making a decision. The ministry is particularly focusing on options for individuals aged 20 to 34.
Market expectations are growing that the hair loss treatment market could expand if health insurance coverage is realized. Consequently, there is heightened interest in pharmaceutical companies that possess relevant technologies and pipelines.
Recently, Samik Pharmaceutical registered a patent for a technology that manufactures polymer microparticles using cyclodextrin complex compounds, securing its long-acting injectable platform technology. This technology serves as a foundational method for developing the JAK inhibitor baricitinib, used for treating alopecia, into a long-acting injectable administered once a month, as opposed to the current oral formulation.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.